COMP <GO>
WGS vs ABBV // RETURN ON INVESTED CAPITAL (ROIC)
GeneDx Holdings Corp. (Class A) (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: WGS 2
— ABBV 9
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: ABBV
LAST: $71.02 (+9.79%) • MKT CAP: $2.12B
roic
-4.10%
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
roic
29.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (WGS VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | WGS | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 69.70% | 70.20% | -0.50 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | -4.10% | 29.00% | -33.10 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 33.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 0.67% | 3.47% | -2.80 | ABBV | /fcf-yield <GO> |
| Operating Margin | -3.10% | 24.60% | -27.70 | ABBV | /operating-margins <GO> |
| Net Profit Margin | -4.90% | 6.90% | -11.80 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | 40.00% | 8.60% | +31.40 | WGS | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.32 | 5.33 | -2.01 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | WGS | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 48.5 | 65.1 | -16.57 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.15 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 113.1x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.12B | $513.86B | -$511.74B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | WGS REV | ABBV REV | WGS GROSS % | ABBV GROSS % | WGS FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $427.5M | $61.16B | 69.7% | 70.2% | $14.3M | $17.82B |
| FY 2024 | $305.4M | $56.33B | 63.6% | 70.0% | -$34.0M | $17.83B |
| FY 2023 | $202.6M | $54.32B | — | — | -$180.1M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
WGS // BETA —
ABBV // BETA 1.15